AUDA manufacturers
- AUDA
-
- $77.00
-
2026-07-14
- CAS:479413-70-2
- Purity: 99.50%
- Supply Ability: 10g
- AUDA
-
-
2026-07-10
- CAS:479413-70-2
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 20Tons
|
| Product Name: | AUDA | | Synonyms: | 12-(3-adamantan-1-yl-ureido)dodecanoic acid;AUDA;12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid;Dodecanoic acid, 12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-;Inhibitor,anti-inflammatory,epoxide,inhibit,hydrolase,sEH,activity,AUDA,soluble,Epoxide Hydrolase,VSMC;AUDA, 10 mM in DMSO;AUDA,≥98%;12-(3-adamantan-1-Y-L-Ureido)dodecaneacid | | CAS: | 479413-70-2 | | MF: | C23H40N2O3 | | MW: | 392.58 | | EINECS: | | | Product Categories: | | | Mol File: | 479413-70-2.mol |  |
| Melting point | 114 °C(Solv: hexane (110-54-3)) | | Boiling point | 592.7±19.0 °C(Predicted) | | density | 1.09±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMSO: ≥10mg/mL at warmed to 60°C | | form | powder | | pka | 4.78±0.10(Predicted) | | color | white to beige | | InChI | 1S/C23H40N2O3/c26-21(27)10-8-6-4-2-1-3-5-7-9-11-24-22(28)25-23-15-18-12-19(16-23)14-20(13-18)17-23/h18-20H,1-17H2,(H,26,27)(H2,24,25,28)/t18-,19+,20-,23- | | InChIKey | XLGSEOAVLVTJDH-UKBVAGSOSA-N | | SMILES | OC(=O)CCCCCCCCCCCNC(=O)NC12C[C@@H]3C[C@@H](C[C@@H](C3)C1)C2 |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| Uses | AUDA is an inhibitor of sEH and selective activator of PPARα. | | Biological Activity | Inhibition of soluble epoxide hydrolase by AUDA inhibits the metabolism of epoxyeicosatrienoic acids (EETs) and protects end-organs against the damaging effects of salt-sensitive hypertension. AUDA also renders protection against myocardial ischemia-reperfusion injury and cerebral ischemia.', 'AUDA is a potent inhibitor of soluble epoxide hydrolase | | in vivo | AUDA (i.p.; 10 mg/kg; 14 days) reduces TNF-α, MMP-9 and IL-1β expression levels[3]. | Animal Model: | Male (wild-type) C57BL/6 mice (age, 4-6 weeks; weight, 18-20 g)[3] | | Dosage: | 10 mg/kg | | Administration: | i.p.; 14 days | | Result: | Reduced TNF-α, MMP-9 and IL-1β expression levels.
|
|
| | AUDA Preparation Products And Raw materials |
|